ÀÓ¼±¹Î
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, À¯¹æ¾Ï, °©»ó¼±¾Ï, ÇǺξÏ, Èñ±Í¾Ï
Á÷
ˤ
: Á¶±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
21
ÇØ¿Ü
Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET-rearranged lung adenocarcinoma
20
ÇØ¿Ü
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
19
ÇØ¿Ü
Screening of ROS1 rearrangement in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
18
ÇØ¿Ü
Clinical implications from a single-center study of colorectal adenocarcinoma in transplant recipients
17
ÇØ¿Ü
An open-label, multicenter, phase II trial of dovitinib in advanced thyroid cancer patients
16
ÇØ¿Ü
Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
15
ÇØ¿Ü
Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
14
ÇØ¿Ü
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer
13
ÇØ¿Ü
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
12
ÇØ¿Ü
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729